Involvement of Central Cholinergic System in Decrease of Serum Fatty Acids After Intracerebroventricular Administration of Chlorpromazine

Total Page:16

File Type:pdf, Size:1020Kb

Involvement of Central Cholinergic System in Decrease of Serum Fatty Acids After Intracerebroventricular Administration of Chlorpromazine INVOLVEMENT OF CENTRAL CHOLINERGIC SYSTEM IN DECREASE OF SERUM FATTY ACIDS AFTER INTRACEREBROVENTRICULAR ADMINISTRATION OF CHLORPROMAZINE Yoko UCHIDA and Teruko NOMOTO Department of Pharmacology, Tokyo Women's Medical College, 10 Kawada-cho, Shinjuku-ku, Tokyo 162, Japan Accepted October 18, 1982 We reported that an injection of chlor Pharmaceutical Co. Ltd., acetylcholine (ACh) promazine (CPZ) into the lateral ventricle chloride: Daiichiseiyaku Co. Ltd., carbamyl caused a transient decrease in serum FFA. choline (CAR) chloride: Sigma Chemical Co. The involvement of the central dopaminergic Ltd., atropine sulfate: lwakiseiyaku Co. Ltd., mechanism in this decrease was considered neostigmine methyl sulfate: Shionogi Phar (1). The dopaminergic-cholinergic an maceutical Co. Ltd.) were dissolved in saline, tagonistic relationship in the nigro-striatal and the solution was adjusted to a pH of system, indicated by metabolic (2-6), 6.8. All doses of drugs used are given in the behavioral (6, 7) and microiontophoretical results as the amount of free base. Blood (8) evidence, is now well known. Therefore, samples for determination of FFA were in order to know the involvement of the obtained from the jugular vein of rats with a central cholinergic system in the control of disposable syringe. Serum FFA was deter peripheral lipid mobilization after intra mined colorimetrically according to the cerebroventricular (i.c.v.) injection of CPZ, method of Novak (9). we examined the effect of cholinergic agents As is described in the previous report (1), on the change in the serum FFA level after the i.c.v. Injection of CPZ produced a marked the i.c.v. injection of CPZ in rats. transient decrease in serum FFA with the two Male Wistar-lmamichi rats weighing 180 doses (200, 500 ug/kg) examined, whereas 280 g were kept in an air-conditioned room the same volume of vehicle (20 ul/kg) had (23±2°C, 55±5% humidity) lighted 14 hr a no effect. Serum FFA levels reached a day (06:00 to 20:00) and maintained on a rat minimum 30 min after injection of CPZ and standard diet and water ad libitum. For then returned to the initial level during the injections into the cerebral ventricles, a second hour. With a lower dose of 100 ug/kg stainless steel cannula was implanted into CPZ, only a slight decrease was observed, but the right lateral ventricle under sodium this was not statistically significant. Micro pentobarbital anesthesia (nembutal, 40 mg/ injection of either ACh alone at a dose of kg i.p.). After a 7-day post-operative recovery 20 ug/kg or carbachol at the same dose did period, drugs were injected through this not affect the serum concentration of FFA. cannula without any anesthesia. All i.c.v. The simultaneous administration of ACh and injections of drugs were made in the same CPZ at 100 ug/kg into the right lateral volume (20 ul/kg) over a period of 20 sec. ventricle accelerated the fall in the serum All the drugs (CPZ hydrochloride: Shionogi FFA level, whereas the simultaneous admin istration of ACh with two higher doses of ACh with 100 fig/kg CPZ was significantly CPZ (200 or 500 ,ag/kg) did not show any blocked by the prior i.c.v. injection of atropine, modification. On the other hand, the fall in indicating that muscarinic synaptic receptors the serum FFA level after CPZ at 100 or are involved in this effect. However, the 200 ug/kg i.c.v. was significantly accelerated potentiation by carbachol was hardly inhibited with the simultaneous injection of 20 ag/kg by preinjection of atropine, suggesting that carbachol. However, at a dose of 500 ug/kg the mechanisms of the potentiation by i.c.v. CPZ, the significant modification carbachol may be different from that by ACh. following the simultaneous injection of After the i.c.v. injection of 5 ag/kg carbachol was not observed. The potentiation neostigmine, the tendency of the opposite by carbachol of CPZ was more pronounced response in the potentiation of CPZ action by and long-lasting than that of ACh (Fig. 1). these two cholinergic agents (ACh, car Further, in an attempt to examine the effect bachol) was observed, even though it was of an anticholinergic agent and anticholi not significant. These results after preinjection nesterase, 50 Jag/kg atropine or 5 ,ag/kg of atropine or neostigmine suggest that neostigmine was injected intracerebroven carbachol produced the potentiation of CPZ triculary 10 min prior to the injection of CPZ, action as well as ACh; but the details of the ACh and carbachol. As shown in Fig. 2, the mechanisms of the action by this drug is potentiation by simultaneous injection of probably different from ACh, i.e., the possible Fig. 1. Effect of simultaneous injection of ACh (20 pg/kg i.c.v.) or carbachol (20 ,ug/kg i.c.v.) alone with CPZ (100, 200, 500 gg/kg) on the decrease in serum FFA. Numbers in parentheses represent the numbers of animals employed. The vertical lines indicate the S.E. of the mean. P values were calculated by the Student's t-test. *P<0.05, **P<0.01 as compared to CPZ alone. involvement of the muscarinic cholinergic nigro-striatal dopamine neurons exert an receptors in the potentiation by ACh of CPZ excitatory (10, 11) or inhibitory (2, 12) effect action was revealed, but presumably not in on cholinergic interneurons in the striatum. the potentiation by carbachol. Furthermore, several reports have shown that On the other hand, it has been already dopamine or dopamine-mimetic drugs inhibits demonstrated that there is an antagonistic the cholinergic cells in the caudate nucleus, relationship between the dopaminergic and reducing ACh turnover or release, and cholinergic system in the striatum (2-8), resulting in an increase in ACh content in this although it remains still controversial whether area. The opposite effect is produced by Fig. 2. Effect of preinjection of atropine (50,ug/kg i.c.v.) or neostigmine (5 jig/kg i.c.v.) on the acceler ation of the decrease in serum FFA after the simultaneous injection of ACh (20 fig/kg i.c.v.) or carbachol (20 pg/kg i.c.v.) with CPZ (100 pg/kg i.c.v.). Atropine or neostigmine was injected 10 min. prior to the injection of CPZ, ACh and carbachol. Values show the mean standard error at 30 min after administration of CPZ, ACh and carbachol. Figures at the foot of each of the columns represent the numbers of animals employed. P values were calculated by the Student's t-test. *P<0 .05, **P<0.01. dopamine antagonists or dopamine-depleting by apomorphine, piribedil and D-amphetamine. agents (2, 4, 13, 14). Brain Res. 84, 221-226 (1975) 5) Ladinsky, H., Consolo, S., Bianchi, B., Ghezzi, In this experiment herein, the effect of D. and Samanin, R.: Link between dopaminergic CPZ on the decrease in serum FFA was and cholinergic neurons in the striatum as potentiated by the cholinergic agents such evidenced by pharmacological, biochemical, as ACh and carbachol. On the contrary, this and lesion studies. In Interactions Between Putative Neurotransmitters in the Brain, Edited effect was blocked by dopamine and apo by Garattini, S., Pujol, J.F. and Samanin, R., morphine as described in our previous report p. 3-21, Raven Press, New York (1978) (1). Now, a possible cholinergic involvement 6) James, T.A. and Massey, S.: Evidence for a in the control of peripheral lipid mobilization possible dopaminergic link in the action of acetylcholine in the rat substantia nigra. Neuro induced by CPZ is also suggested. It is pharmacology 17, 687-690 (1978) therefore possible to say that the central 7) Neill, D.B.: Frontal-striatal control of behavioral dopaminergic-cholinergic system is involved inhibition in the rat. Brain Res. 105, 89-103 in the peripheral lipid mobilization induced (1976) 8) Aghajanian, G.K. and Bunney, B.S.: Dopami by CPZ. nergic and non-dopaminergic neurons of the Acknowledgement: We thank Prof. substantia nigra: differential responses to Tonoue, Department of Physiology II, Azabu putative transmitters. Neuropsychopharmac ology, Edited by Boissier, J.R., Hippius, H. and University, for comments on the manuscript. Pichot, P., p. 444-452, Excerpta Medica , This work was supported in part by grant Amsterdam (1974) 567037 from the Ministry of Education, 9) Novak, M.: Colorimetric ultramicro method for Science and Culture, Japan. the determination of free fatty acids. J. Lipid Res. 6, 431-433 (1965) 10) Kitai, S.T., Sugimori, M. and Kocsis, J.D.: References Exitatory nature of dopamine in the nigro 1) Uchida, Y. and Nomoto, T.: Effect of intra caudate pathway. Exp. Brain Res. 24, 351-363 cerebroventricular administration of chlor (1976) promazine on the serum level of free fatty acids 11) Butcher, S.H., Butcher, L.L. and Cho, A.K.: in rats. Japan. J. Pharmacol. 32, 709-718 Modulation of neostriatal acetylcholine in the (1982) rat by dopamine and 5-hydroxytryptamine 2) McGeer, P.L., Grewaal, D.S. and McGeer, afferents. Life Sci. 18, 733-744 (1976) E.G.: Influence of noncholinergic drugs on rat 12) McLennan, H. and York, D.H.: The action of striatal acetylcholine levels. Brain Res. 80, 211 dopamine on neurones of the caudate nucleus. 217 (1974) - J. Physiol. 189, 393-402 (1967) 3) Guyenet, P.G., Agid, Y., Javoy, F., Beaujouan, 13) Stadler, H., Lloyd, K.G., Gadea-Ciria, M. and J.C., Rossier, J. and Glowinski, J.: Effects of Bartholini, G.: Enhanced striatal acetylcholine dopaminergic receptor agonists and antagonists release by chlorpromaizine and its reversal by on the activity of the neo-striatal cholinergic apomorphine. Brain Res. 55, 476-480 (1973) system.
Recommended publications
  • Proprietary Name Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 22-562 PROPRIETARY NAME REVIEW(S) Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Date: February 24, 2010 Donna Griebel, MD To: Director, Division of Gastroenterology Products Denise Toyer, Pharm.D., Deputy Director Through: Carol Holquist, R.Ph., Director Division of Medication Error Prevention and Analysis Zachary Oleszczuk, PharmD, Acting Team Leader From: Division of Medication Error Prevention and Analysis Subject: Proprietary Name Review Carbaglu (Carglumic Acid) Tablets Drug Name(s): 200 mg Application Type/Number: NDA 022562 Applicant: Orphan Europe, SARL OSE RCM #: 2009-2140 CONTENTS 1 INTRODUCTION......................................................................................................................................... 3 2 METHODS.................................................................................................................................................... 3 3 RESULTS...................................................................................................................................................... 3 4 CONCLUSIONS AND RECOMMENDATIONS........................................................................................ 3 5 REFERENCES.............................................................................................................................................. 3 2 1 INTRODUCTION This
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’
    0270.6474/85/0505-1202$02.00/O The Journal of Neuroscience CopyrIght 0 Society for Neuroscrence Vol. 5, No. 5, pp. 1202-1207 Printed in U.S.A. May 1985 Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’ EDWIN M. MEYER* AND DEBORAH H. OTERO Department of Pharmacology and Therapeutics, University of Florida School of Medicine, Gainesville, Florida 32610 Abstract brain (Gonzales and Crews, 1984). M,-receptors, however, appear pre- and postsynaptically in brain, are regulated by an intrinsic The muscarinic receptors that modulate acetylcholine membrane protein that binds to GTP (g-protein), and may not be release from rat cortical synaptosomes were characterized coupled to changes in phosphatidylinositol turnover. with respect to sensitivity to drugs that act selectively at M, The present studies were designed to determine whether M,- or or Ma receptor subtypes, as well as to changes in ionic Mp-receptors mediate the presynaptic modulation of ACh release. strength and membrane potential. The modulatory receptors These studies involve dose-response curves for the release of appear to be of the M2 type, since they are activated by synaptosomal [3H]ACh in the presence of selected muscarinic ago- carbachol, acetylcholine, methacholine, oxotremorine, and nists and antagonists, as well as treatments that selectively alter MI- bethanechol, but not by pilocarpine, and are blocked by or M,-receptor activity. Our results indicate that the presynaptic atropine, scopolamine, and gallamine (at high concentra- modulation of [3H]ACh release is mediated by MP- but not MI- tions), but not by pirenzepine or dicyclomine.
    [Show full text]
  • Pharmacology of Ophthalmologically Important Drugs James L
    Henry Ford Hospital Medical Journal Volume 13 | Number 2 Article 8 6-1965 Pharmacology Of Ophthalmologically Important Drugs James L. Tucker Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Chemicals and Drugs Commons, Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Tucker, James L. (1965) "Pharmacology Of Ophthalmologically Important Drugs," Henry Ford Hospital Medical Bulletin : Vol. 13 : No. 2 , 191-222. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol13/iss2/8 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. Henry Ford Hosp. Med. Bull. Vol. 13, June, 1965 PHARMACOLOGY OF OPHTHALMOLOGICALLY IMPORTANT DRUGS JAMES L. TUCKER, JR., M.D. DRUG THERAPY IN ophthalmology, like many specialties in medicine, encompasses the entire spectrum of pharmacology. This is true for any specialty that routinely involves the care of young and old patients, surgical and non-surgical problems, local eye disease (topical or subconjunctival drug administration), and systemic disease which must be treated in order to "cure" the "local" manifestations which frequently present in the eyes (uveitis, optic neurhis, etc.). Few authors (see bibliography) have attempted an introduction to drug therapy oriented specifically for the ophthalmologist. The new resident in ophthalmology often has a vague concept of the importance of this subject, and with that in mind this paper was prepared.
    [Show full text]
  • The Use of Central Nervous System Active Drugs During Pregnancy
    Pharmaceuticals 2013, 6, 1221-1286; doi:10.3390/ph6101221 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review The Use of Central Nervous System Active Drugs During Pregnancy Bengt Källén 1,*, Natalia Borg 2 and Margareta Reis 3 1 Tornblad Institute, Lund University, Biskopsgatan 7, Lund SE-223 62, Sweden 2 Department of Statistics, Monitoring and Analyses, National Board of Health and Welfare, Stockholm SE-106 30, Sweden; E-Mail: [email protected] 3 Department of Medical and Health Sciences, Clinical Pharmacology, Linköping University, Linköping SE-581 85, Sweden; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +46-46-222-7536, Fax: +46-46-222-4226. Received: 1 July 2013; in revised form: 10 September 2013 / Accepted: 25 September 2013 / Published: 10 October 2013 Abstract: CNS-active drugs are used relatively often during pregnancy. Use during early pregnancy may increase the risk of a congenital malformation; use during the later part of pregnancy may be associated with preterm birth, intrauterine growth disturbances and neonatal morbidity. There is also a possibility that drug exposure can affect brain development with long-term neuropsychological harm as a result. This paper summarizes the literature on such drugs used during pregnancy: opioids, anticonvulsants, drugs used for Parkinson’s disease, neuroleptics, sedatives and hypnotics, antidepressants, psychostimulants, and some other CNS-active drugs. In addition to an overview of the literature, data from the Swedish Medical Birth Register (1996–2011) are presented. The exposure data are either based on midwife interviews towards the end of the first trimester or on linkage with a prescribed drug register.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • (19) 11 Patent Number: 6165500
    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Drugs/Medications Known to Cause Diaphoresis
    Drugs/Medications Known to Cause Diaphoresis Certain prescription and non-prescription medications can cause diaphoresis (excess perspiration or sweating) as a side effect. A list of potentially sweat-inducing medications is provided below. Medications are listed alphabetically by generic name. U.S. brand names are given in parentheses, if applicable. This list is provided as a resource and a service. It is not exhaustive and is in no way meant to replace consultation with a medical professional. Although sweating is a known side effect of the medications listed below, in most cases only a small percentage of people using the medicines experience undue sweating (in some cases less than 1%). Medications noted with an “*” are the most likely to cause sweating and the frequency of sweating as a side effect from these medications may be as high as 50%. Abciximab (ReoPro®) Acamprosate (Campral®) Acetaminophen and Tramadol (Ultracet™) Acetophenazine (NA) Acetylcholine (Miochol-E®) Acetylcysteine (Acetadote®) Acitretin (Soriatane®) Acrivastine and Pseudoephedrine (Semprex®-D) Acyclovir (Zovirax®) Adenosine (Adenocard®; Adenoscan®) Alemtuzumab (Campath®) Almotriptan (Axert™) Alosetron (Lotronex®) Ambenonium (Mytelase®) Amitriptyline (Elavil®) Amlodipine (Norvasc®) Amoxapine (NA) Amphotericin B (Liposomal) (AmBisome®) Anastrozole (Arimidex®) Anidulafungin (Eraxis™) Antihemophilic Factor (Recombinant) (Advate; Helixate® FS; Kogenate® FS; Recombinate™; ReFacto®) Antithymocyte Globulin (Equine) (Atgam®) Antithymocyte Globulin (Rabbit) (Thymoglobulin®)
    [Show full text]
  • Drugs Which Can Affect Near Vision: a Useful List
    Drugs Which Can Affect Near Vision: A Useful List Joanne L. Smith B.Sc., Ph.Phm.* J. Raymond Buncic, M.D., F.R.C.S.(C)t ABSTRACT This paper documents a list of drugs that cause problems with near vision, by virtue of effects on accommodation, occasionally refractive error and diplopia. It is meant as a reference aid to the clinician when confronted with problems of focusing on near objects or print. There are many drugs that have been reported to interfere with near or reading vision, producing blurring, decreased accommodation and diplopia. This paper lists the drugs that have been reported in the literature to produce symptoms which interfere with near vision. Case reports for the listed drugs vary greatly from many to few. The drugs have been divided into the following categories: those causing (A) blurring at near, (B) diplopia and (C) induced myopia. Those drugs which only rarely cause these symptoms have been omitted. From the Departments of Pharmacy* and Ophthalmologyt, The Hospital For Sick Children, Toronto, Ontario, Canada Requests for reprints should be addressed to: Dr. J. Raymond Buncic, Department of Ophthalmology, The Hospital For Sick Children, 555 University Ave., Toronto, Ontario, Canada M5G lX8 TABLE 1 DRUGS COMMONLY CAUSING DIFFICULTY WITH FOCUSING AT NEAR OR BLURRED VISION. DRUG INCIDENCE REFERENCE Antipsychotics Chlorpromazine 14-23 8 Clozapine 5 8,14 Fluphenazine 1.2-4.3 8 Haloperidol 6.8-16 8 Loxapine 12,14 Perphenazine 7.4-17.8 8 Pimozide 20 8 Risperidone 1-2%, >/= 10% 11 Thioridazine 0.6-18 8 Thiothixene 20 8
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]